Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer

Journal of Urology

Volumn 184, Issue 4, 2010, Pages 1316-1321

  Smith, Matthew R ^a   Morton, Ronald A ^b   Barnette, K Gary ^b   Sieber, Paul R ^c   Malkowicz, S Bruce ^d   Rodriguez, Domingo ^b   Hancock, Michael L ^b   Steiner, Mitchell S ^b  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b GTx Inc   (United States)

^c Urological Associates of Lancaster   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

osteoporosis; prostatic neoplasms; selective estrogen receptor modulators; toremifene

Indexed keywords

ANDROGEN; LIPID; PLACEBO; TOREMIFENE; ANTIANDROGEN; BONE DENSITY CONSERVATION AGENT;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTHRALGIA; ARTICLE; BACKACHE; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG WITHDRAWAL; FEMUR NECK; FRAGILITY FRACTURE; HUMAN; LIPID BLOOD LEVEL; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; STATISTICAL SIGNIFICANCE; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE; CHEMICALLY INDUCED; FRACTURES, BONE; MIDDLE AGED; PROSPECTIVE STUDY; PROSTATIC NEOPLASMS; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; BONE DENSITY CONSERVATION AGENTS; DOUBLE-BLIND METHOD; FRACTURES, BONE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK FACTORS; TOREMIFENE;

EID: 78649352694     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2010.06.022     Document Type: Article

References (28)

1. A. Jemal, R. Siegel, and E. Ward Cancer statistics, 2008 CA Cancer J Clin 58 2008 71
2. N. Sharifi, J.L. Gulley, and W.L. Dahut Androgen deprivation therapy for prostate cancer JAMA 294 2005 238
3. V.B. Shahinian, Y.F. Kuo, and J.L. Freeman Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma Cancer 103 2005 1615
4. A. Falahati-Nini, B.L. Riggs, and E.J. Atkinson Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men J Clin Invest 106 2000 1553
5. V.B. Shahinian, Y.F. Kuo, and J.L. Freeman Risk of fracture after androgen deprivation for prostate cancer N Engl J Med 352 2005 154
6. M.R. Smith, W.C. Lee, and J. Brandman Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer J Clin Oncol 23 2005 7897
7. National Osteoporosis Foundation Men and osteoporosis www.nof.org/men Accessed July 14, 2010
8. E. Seeman The structural basis of bone fragility in men Bone 25 1999 143
9. P.R. Ebeling Clinical practice Osteoporosis in men N Engl J Med 358 2008 1474
10. H.K. Genant Assessment of vertebral fractures in osteoporosis research J Rheumatol 24 1997 1212
11. M.R. Smith, J.S. Finkelstein, and F.J. McGovern Changes in body composition during androgen deprivation therapy for prostate cancer J Clin Endocrinol Metab 87 2002 599
12. M.E. Mendelsohn, and R.H. Karas The protective effects of estrogen on the cardiovascular system N Engl J Med 340 1999 1801
13. A. Schwandt, and J.A. Garcia Complications of androgen deprivation therapy in prostate cancer Curr Opin Urol 19 2009 322
14. L.R. Wiseman, and K.L. Goa Toremifene A review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer Drugs 54 1997 141
15. M.S. Steiner, A. Patterson, and R. Israeli Toremifene citrate versus placebo for treatment of bone loss and other complications of androgen deprivation therapy in patients with prostate cancer abstract J Clin Oncol 22 2004 abstract 4597
16. SAS Institute, Inc SAS/STAT 9.1 User's Guide 2004 SAS Institute, Inc Cary, North Carolina
17. N. Mantel, and W. Haenszel Statistical aspects of the analysis of data from retrospective studies of disease J Natl Cancer Inst 22 1959 719
18. N.E. Breslow, and N.E. Day Statistical Methods in Cancer Research Volume 1- the Analysis of Case-Control Studies IARC Scientific Publications No. 32 1980 International Agency for Research on Cancer Lyon, France
19. M. Zelen The analysis of several 2 x 2 contingency tables Biometrika 58 1971 129
20. B. Ettinger, D.M. Black, and B.H. Mitlak Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators JAMA 282 1999 637
21. M.R. Smith, M.A. Fallon, and H. Lee Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial J Clin Endocrinol Metab 89 2004 3841
22. M.R. Smith, J. Eastham, and D. Gleason Randomized controlled trial of zoledronic acid to prevent bone loss in men undergoing androgen deprivation therapy for nonmetastatic prostate cancer J Urol 169 2003 2008
23. S.L. Greenspan, J.B. Nelson, and D.L. Trump Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial Ann Intern Med 146 2007 416
24. M.R. Smith, B. Egerdie, and N. Hernandez Toriz Denosumab in men receiving androgen-deprivation therapy for prostate cancer N Engl J Med 361 2009 745
25. L.J. Melton 3rd, E.J. Atkinson, and C. Cooper Vertebral fractures predict subsequent fractures Osteoporos Int 10 1999 214
26. M. Naves, J.B. Diaz-Lopez, and C. Gomez The effect of vertebral fracture as a risk factor for osteoporotic fracture and mortality in a Spanish population Osteoporos Int 14 2003 520
27. N.L. Keating, A.J. O'Malley, and M.R. Smith Diabetes and cardiovascular disease during androgen deprivation for prostate cancer J Clin Oncol 24 2006 4448
28. P.J. Saylor, and M.R. Smith Metabolic complications of androgen deprivation therapy for prostate cancer J Urol 181 2009 1998